Tags

Type your tag names separated by a space and hit enter

Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients.
Diabete Metab. 1992 May-Jun; 18(3):221-8.DM

Abstract

Correction of cardiovascular risk factors is of particular significance in a high-risk population, such as that of diabetic patients. This paper reports the effects of one-month administration of 400 mg/day Bezafibrate (BZF), followed by a two-month wash-out and one-month administration of 500 mg/day Acipimox (APX) or vice versa in a random order in 16 Type 2 diabetic patients with diet-resistant hyperlipidaemia and in good metabolic control (HbA1c less than 8%), on plasma fibrinogen and on their lipid pattern. Metabolic control displayed a nonsignificant improvement (HbA1c) during both treatments (stable body weight). Both BZF and APX produced a 14% decrease in total CHOL (p less than 0.01), whereas BZF was more effective in reducing triglycerides (tg) (-37% vs -15%). The marked BZF-induced Tg reduction was associated with a proportional decrease in Apo B, while an increase in total HDL-, HDL2 and HDL3-CHOL, together with a significant increase in Apo AI, was observed. APX treatment resulted in a HDL2-CHOL increase only (+29%). Both drugs reduced VLDL-CHOL (BZF -37%; APX -15%) and VLDL-Tg (-56% and -34%). In BZF treated patients Apo CIII fell indicating a possible reduction of specific inhibition of lipoprotein lipase activity, while APX affected both Apo CII (+23%) and Apo CIII (-26%) and led to a 62% Apo CII/CIII ratio increase. BZF alone led to a significant 25% decrease in plasma fibrinogen (from 415 +/- 14.3 to 312.1 +/- 18.1 SEM mg/dl, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Istituto di Medicina Interna, University of Torino, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1397477

Citation

Niort, G, et al. "Comparison of the Effects of Bezafibrate and Acipimox On the Lipid Pattern and Plasma Fibrinogen in Hyperlipidaemic Type 2 (non-insulin-dependent) Diabetic Patients." Diabete & Metabolisme, vol. 18, no. 3, 1992, pp. 221-8.
Niort G, Cassader M, Gambino R, et al. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1992;18(3):221-8.
Niort, G., Cassader, M., Gambino, R., & Pagano, G. (1992). Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients. Diabete & Metabolisme, 18(3), 221-8.
Niort G, et al. Comparison of the Effects of Bezafibrate and Acipimox On the Lipid Pattern and Plasma Fibrinogen in Hyperlipidaemic Type 2 (non-insulin-dependent) Diabetic Patients. Diabete Metab. 1992 May-Jun;18(3):221-8. PubMed PMID: 1397477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients. AU - Niort,G, AU - Cassader,M, AU - Gambino,R, AU - Pagano,G, PY - 1992/5/1/pubmed PY - 2000/3/11/medline PY - 1992/5/1/entrez SP - 221 EP - 8 JF - Diabete & metabolisme JO - Diabete Metab VL - 18 IS - 3 N2 - Correction of cardiovascular risk factors is of particular significance in a high-risk population, such as that of diabetic patients. This paper reports the effects of one-month administration of 400 mg/day Bezafibrate (BZF), followed by a two-month wash-out and one-month administration of 500 mg/day Acipimox (APX) or vice versa in a random order in 16 Type 2 diabetic patients with diet-resistant hyperlipidaemia and in good metabolic control (HbA1c less than 8%), on plasma fibrinogen and on their lipid pattern. Metabolic control displayed a nonsignificant improvement (HbA1c) during both treatments (stable body weight). Both BZF and APX produced a 14% decrease in total CHOL (p less than 0.01), whereas BZF was more effective in reducing triglycerides (tg) (-37% vs -15%). The marked BZF-induced Tg reduction was associated with a proportional decrease in Apo B, while an increase in total HDL-, HDL2 and HDL3-CHOL, together with a significant increase in Apo AI, was observed. APX treatment resulted in a HDL2-CHOL increase only (+29%). Both drugs reduced VLDL-CHOL (BZF -37%; APX -15%) and VLDL-Tg (-56% and -34%). In BZF treated patients Apo CIII fell indicating a possible reduction of specific inhibition of lipoprotein lipase activity, while APX affected both Apo CII (+23%) and Apo CIII (-26%) and led to a 62% Apo CII/CIII ratio increase. BZF alone led to a significant 25% decrease in plasma fibrinogen (from 415 +/- 14.3 to 312.1 +/- 18.1 SEM mg/dl, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0338-1684 UR - https://www.unboundmedicine.com/medline/citation/1397477/Comparison_of_the_effects_of_bezafibrate_and_acipimox_on_the_lipid_pattern_and_plasma_fibrinogen_in_hyperlipidaemic_type_2__non_insulin_dependent__diabetic_patients_ L2 - https://medlineplus.gov/cholesterolmedicines.html DB - PRIME DP - Unbound Medicine ER -